Skip to content
Menu

PaxMedica, Inc. PXMD

Full chart Compare
Set alert

Price alert · PXMD

All alert types
0.00 USD 0.00 (+0.00%)

Regular-session close

0.0001 Day range 0.0001
0.0001 52-week range 0.02
YTD
+400.00%
1 year
+400.00%

 

No chart data for this range yet.
Market cap
63.13K
EPS (ttm)
166.20
Shares out
7.78M
P/E ratio
0.00
Forward P/E
-0.29
YTD return
+400.00%
1-year return
+400.00%
Volume
300
Avg volume
1.52K
Open
0.0001
Previous close
0.0005
Day's range
0.0001 – 0.0001
52-week range
0.0001 – 0.02
Price target
3.00 (+599900.0%)

Key statistics

50-day average
0.50136
200-day average
2.33
Enterprise value
809.76K
Price / book
1.97
Free cash flow
-5.31M
Total cash
1.63M
Return on equity
-975.03%
Short % of float
8.62%

Fundamental scorecard

5 of 25 checks passed on PXMD’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Dec 31, 2023.

Financials — quick view

All financials
PXMD Revenue — quarterly 0
PXMD Net income — quarterly -5.92M
PXMD EPS — quarterly 3.39

Earnings

PXMD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 25, 2024Sep 1, 20240.00———
Sep 20, 2024Jun 1, 20240.00-0.39——
May 13, 2024Mar 1, 2024-0.43-0.50-0.07-16.28%
Apr 3, 2024Dec 1, 2023-0.88———
Nov 15, 2023Sep 1, 20230.00-5.20——
Aug 9, 2023Jun 1, 20230.00-4.08——

About PaxMedica, Inc.

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on PXMD — it syncs with the Stock Master app.

Insider holders

PXMD insider holders
InsiderRelationLatest transactionDateShares held
CASAMENTO CHARLES JDirectorStock Award(Grant)Apr 12, 202365,583
COELHO JOHN F.DirectorSaleJan 28, 20244,615
DERBY MICHAELBeneficial Owner of more than 10% of a Class of SecuritySaleNov 26, 2023457,224
HOUGH DAVID WOfficerStock Award(Grant)Oct 22, 2023130,000
LAROCHELLE KARENDirectorSaleJan 28, 20242,829
ROME ZACHARYDirectorSaleJan 28, 202415,148

Institution ownership

PXMD institution ownership
Holder% heldSharesValueReported
Citadel Advisors Llc0.42%68,99154.23KJun 29, 2023
Vanguard Group Inc0.33%54,95943.20KJun 29, 2023
Geode Capital Management, LLC0.19%30,78124.19KJun 29, 2023
HRT Financial LP0.16%25,98220.42KJun 29, 2023
State Street Corporation0.13%21,90017.21KJun 29, 2023
Tower Research Capital LLC (TRC)0.05%7,7466.09KJun 29, 2023

Fund ownership

PXMD fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund0.33%54,95943.20KJun 29, 2023
Fidelity Extended Market Index Fund0.17%27,35336.65KMay 30, 2023
Fidelity NASDAQ Composite Index Fund0.02%2,9793.99KMay 30, 2023